Pharming Group - Stock Price History | PHGUF

Historical daily share price chart and data for Pharming Group since 1969 adjusted for splits. The latest closing stock price for Pharming Group as of December 31, 1969 is 0.00.
  • The all-time high Pharming Group stock closing price was 0.00 on December 31, 1969.
  • The Pharming Group 52-week high stock price is 0.00, which is NAN% above the current share price.
  • The Pharming Group 52-week low stock price is 0.00, which is NAN% below the current share price.
  • The average Pharming Group stock price for the last 52 weeks is NaN.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Pharming Group Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.576B $0.212B
Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29